- Home
- EQNR vs REGN Comparison
EQNR vs REGN Comparison
Compare EQNR & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EQNR | REGN |
|---|---|---|
| Founded | 1972 | 1988 |
| Country | Norway | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.0B | 84.3B |
| IPO Year | 2002 | 1995 |
Fundamental Metrics
Financial Performance| Metric | EQNR | REGN |
|---|---|---|
| Price | $45.61 | $968.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 28 |
| Target Price | $40.71 | ★ $976.44 |
| AVG Volume (30 Days) | ★ 4.3M | 727.3K |
| Earning Date | 10-28-2026 | 10-30-2026 |
| Dividend Yield | ★ 3.44% | 0.39% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 37.37 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $25.76 | $22.74 |
| Revenue Next Year | N/A | $13.79 |
| P/E Ratio | ★ $14.56 | $25.78 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $22.26 | $591.52 |
| 52 Week High | $49.08 | $974.00 |
Technical Indicators
Market Signals| Indicator | EQNR | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 82.50 |
| Support Level | $40.84 | $736.27 |
| Resistance Level | $45.84 | N/A |
| Average True Range (ATR) | 1.15 | 25.78 |
| MACD | -0.17 | 19.81 |
| Stochastic Oscillator | 9.01 | 97.93 |
Price Performance
Historical ComparisonAbout EQNR Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2025 (50% liquids) and ended 2025 with 5.2 billion barrels of proven reserves (45% liquids). Operations also include oil refineries and natural gas processing, marketing, and trading. The renewables portfolio includes offshore and onshore wind and solar, with total power generation of 5.65 TWh in 2025.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.